Three million people worldwide are taking the new, heavily advertised anti-cholesterol drugs Zetia and Vytorin, despite a lack of clinical evidence that they reduce cardiovascular disease or heart attacks, or help patients live longer. Vytorin and Zetia brought in $5.2 billion last year for Merck and Schering-Plough, placing them among the best-selling drugs in the world. The Food and Drug Administration approves many drugs based on whether they perform a specific action, like lowering cholesterol, without requiring long-term trials on whether they extend life or lower disease risks. Other FDA-approved drugs have been found to be ineffective or even dangerous.
Best-Selling Cholesterol Drugs Found Ineffective
When abortion restrictions are in the news, as they have been for several weeks, research shows...
Yet another item that may be in your pantry has been recalled over possible salmonella contamination.
A...
By the time the American surgeon who contracted Ebola in Congo was flown to Germany for...
The Trump administration has announced a plan to kill Biden-era drinking water limits on four Pfas...
